HE Dr. Ferozuddin Feroz,
The Minister of Public Health
Ministry of Public Health
Great Masoud Road
Kabul
Afghanistan

25 September 2017

Decision Letter: Afghanistan application for Gavi New Vaccine Support – Rotavirus vaccine

Your Excellency,

I am writing in relation to Afghanistan’s application for New Vaccines Support (NVS) for the introduction of rotavirus vaccine in your country’s routine immunisation schedule (rotavirus routine), which was submitted to the Gavi Secretariat in January 2017, and the response to clarifications submitted in May 2017.

Following the recommendations made by the Independent Review Committee (IRC), I am pleased to inform you that Gavi has approved Afghanistan’s application for rotavirus routine immunisation support, subject to the conditions and requirements specified in Appendix A to this letter.

Please do not hesitate to contact my colleague Mr Ricard Lacort, Senior Country Manager for Afghanistan, at rlacort@gavi.org if you have any questions or concerns.

Yours sincerely,

Hind Khatib-Othman
Managing Director, Country Programmes

Appendix A: Afghanistan support for rotavirus vaccine
cc: The Minister of Finance
    The EPI Manager
    WHO Country Representative
    UNICEF Country Representative
    Regional Working Group
    WHO HQ
    UNICEF Programme Division
    UNICEF Supply Division
This Decision Letter sets out the Programme Terms of a Programme.

1. **Country**: Afghanistan
2. **Grant number**: 1819-AFG-13b-X / 18-AFG-08b-Y
3. **Date of Decision Letter**: 25/09/2017
4. **Date of the Partnership Framework Agreement**: 30/04/2013
5. **Programme title**: New Vaccine Support (NVS), rotavirus routine
6. **Vaccine type**: rotavirus
7. **Requested product presentation and formulation of vaccine**: RV1, 1 dose/plastic tube, liquid, 2 dose schedule
8. **Programme duration**: 2018 - 2019
9. **Programme Budget (indicative)**: (subject to the terms of the partnership framework agreement, if applicable)

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2019</th>
<th>Total²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programme Budget (US$)</td>
<td>5,393,500</td>
<td>5,052,500</td>
<td>10,446,000</td>
</tr>
</tbody>
</table>

10. **Vaccine introduction grant**: US$977,902. Payable up to six months before vaccine introduction.
11. **Indicative Annual Amounts**: (subject to the terms of the Partnership Framework Agreement, if applicable)³

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of rotavirus vaccines doses</td>
<td>2,595,000</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>5,393,500</td>
</tr>
</tbody>
</table>

12. **Procurement agency**: UNICEF. The Country shall release its co-financing payments each year to UNICEF.
13. **Self-procurement**: Not applicable.
14. **Co-financing obligations**: Reference code: 1819-AFG-13b-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payments and quantity of supply that will be procured with such funds in the relevant year.

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Country funds in each year</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of rotavirus vaccines doses</td>
<td>277,500</td>
<td>259,500</td>
</tr>
<tr>
<td>Value of rotavirus vaccine doses (US$)</td>
<td>556,284</td>
<td>521,135</td>
</tr>
<tr>
<td>Total co-financing payments (US$) (including freight)</td>
<td>574,500</td>
<td>538,500</td>
</tr>
</tbody>
</table>

15. **Operational support for campaigns**: Not applicable

---

¹ This is the entire duration of the Programme.
² This is the total amount endorsed by Gavi for the entire duration of the Programme.
³ This is the amount that Gavi has approved.
16. Additional reporting requirements:

Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts:

<table>
<thead>
<tr>
<th>Reports and other information</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td>
<td>Annually: on 15 May</td>
</tr>
<tr>
<td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td>
<td>To be agreed with Secretariat</td>
</tr>
</tbody>
</table>

17. Financial clarifications: Not Applicable

18. Other conditions: Not Applicable

Signed by,

[Signature]

On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
25 September 2017